ABSTRACT
Objective To assess the contribution of contrast-enhanced spectral mammography (CESM) in detecting breast carcinoma of dense breasts. Methods To retrospectively analyze the imaging and clinical data of 52 female patients with breast carcinoma which were confirmed by pathology in Tai'an Central Hospital of Shandong Province from April 2017 to April 2018.All cases classified as dense or uneven dense breasts by DM examination underwent Ultrasound (US), digital mammography (DM), CESM, dynamic contrast enhanced MRI (DCE-MRI).The breast imaging report and data system (BI-RADS) and breast density classification were both evaluated using the 5th edition of BI-RADS. The efficacy of US, DM, DM+CESM, DCE-MRI in detecting breast carcinoma (BI-RADS 5) was evaluated by χ2 test. Results Histopathology confirmed that 87 lesions were malignant and 35 lesions were benign. The sensitivity of US, DM, DM +CESM, DCE-MRI were 66.67％(58/87), 64.37％(56/87), 100.00％(87/87), 100.00％(87/87) and the specificity were 94.28％(33/35), 74.28％(26/35), 85.71％(30/35), 51.43％(18/35), respectively. There was statistically significant difference in specificity (χ2=9.545, P=0.002) and BI-RADS 5 category, detection 39.08％(34/87), 22.99％(20/87), respectively (χ2=5.263, P=0.022) between the DM + CESM group and DCE-MRI group. Conclusion In dense breasts, CESM has a high application value in breast carcinoma diagnosis.
ABSTRACT
The successful separation of breast cancer stem cells (BCSCs) is the foundation of BCSC research.At present,people could gather BCSCs to some extent in a number of ways.However,as more and more biomarkers are found in BCSCs separation,the heterogeneity becomes a hot spot.How to gather BCSCs as much as possible and how to explain the heterogeneity could provide new insights in the treatment of breast cancer.
ABSTRACT
Objective: This study aims to investigate the neoadjuvant chemotherapy effect of TC and TEC by detecting the change of circulating tumor cells (CTC) in peripheral blood before and after every neoadjuvant cycle of breast cancer patients. Meth-ods:A total of 96 locally advanced breast cancer patients were selected in our hospital from January 2010 to December 2012. These pa-tients were divided into TC (docetaxel and cyclophosphamide) group and TEC (docetaxel, epirubicin and cyclophosphamide) group. Ve-nous blood (5 mL) was extracted from 96 patients prior to neoadjuvant chemotherapy, 48 h after the first, second, third, and fourth cy-cles of neoadjuvant chemotherapy. The CTC values of these two groups of patients were detected by flow cytometry, and their chemo-therapy effect was compared. Results: No significant difference was observed for age, menopausal status, ER, PR, C-erbB-2, tumor size, and clinical stage between the two groups of patients before chemotherapy and for CTC between the two groups before chemother-apy. Before neoadjuvant chemotherapy, the CTC values were correlated with tumor size. The CTC values for patients with tumor size>5 cm were higher than those with tumor size<5 cm. After neoadjuvant chemotherapy, the CTC values of the two groups of patients de-creased (P<0.05), and the CTC values of the TEC group were lower than those of the TC group (P<0.05). Conclusion:After TC or TEC neoadjuvant chemotherapy, the tumors of patients were smaller, and the CTC values were lower than those prior to neoadjuvant chemotherapy. The efficacy of neoadjuvant chemotherapy can be evaluated by monitoring the values of circulating tumor cells in pe-ripheral blood changes.
ABSTRACT
The vaccine based on dendritic ceil has becomes a new research focus in the biotherapy of breast cancer. And the ways of making the vaccine are vary and no one approach has been shown to be superior to another.